Related Experiment Video
Updated: Feb 12, 2026
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma
Stephen A Jannetti1,2,3, Giuseppe Carlucci3,4, Brandon Carney3,5,6
1Department of Biochemistry, Hunter College-The City University of New York, New York, New York.
Abstract:
The DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1) is overexpressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific small molecule inhibitors, PARP-1 is a near-ideal target to develop novel radiotherapeutics to induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. Methods: We synthesized an 131I-labeled PARP-1 therapeutic and investigated its pharmacology in vitro and in vivo. A subcutaneous tumor model was used to quantify retention times and therapeutic efficacy. A potential clinical scenario, intratumoral convection-enhanced delivery, was mimicked using an orthotopic glioblastoma model combined with an implanted osmotic pump system to study local administration of 131I-PARPi (PARPi is PARP inhibitor). Results:131I-PARPi is a 1(2H)-phthalazinone, similar in structure to the Food and Drug Administration-approved PARP inhibitor AZD-2281. In vitro studies have shown that 131I-PARPi and AZD-2281 share similar pharmacologic profiles. 131I-PARPi delivered 134.1 cGy/MBq intratumoral injected activity. Doses to nontarget tissues, including liver and kidney, were significantly lower. Radiation damage and cell death in treated tumors were shown by p53 activation in U87-MG cells transfected with a p53-bioluminescent reporter. Treated mice showed significantly longer survival than mice receiving vehicle (29 vs. 22 d, P < 0.005) in a subcutaneous model. Convection-enhanced delivery demonstrated efficient retention of 131I-PARPi in orthotopic brain tumors, while quickly clearing from healthy brain tissue. Conclusion: Our results demonstrate 131I-PARPi's high potential as a therapeutic and highlight PARP's relevance as a target for radionuclide therapy. Radiation plays an integral role in brain tumor therapy, and radiolabeled PARP therapeutics could ultimately lead to improvements in the standard of care.
Insights
A novel radioactive drug targeting poly(ADP-ribose) polymerase 1 (PARP-1) shows promise for glioblastoma treatment. This radiotherapeutic induces DNA damage in cancer cells while sparing healthy brain tissue, improving survival rates.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Biology
Background:
- Poly(ADP-ribose) polymerase 1 (PARP-1) is overexpressed in glioblastoma, making it a viable therapeutic target.
- Small molecule inhibitors of PARP-1 are available, paving the way for targeted radiotherapeutics.
- Developing radiotherapeutics that induce DNA damage and apoptosis in cancer cells while sparing healthy tissue is a key goal.
Purpose of the Study:
- To synthesize and evaluate an 131I-labeled PARP-1 inhibitor (131I-PARPi) as a novel radiotherapeutic for glioblastoma.
- To investigate the in vitro and in vivo pharmacology of 131I-PARPi.
- To assess the efficacy and safety of 131I-PARPi using both subcutaneous and orthotopic glioblastoma models.
Main Methods:
- Synthesis of an 131I-labeled PARP-1 inhibitor (131I-PARPi).
- In vitro and in vivo pharmacological studies, including retention times and therapeutic efficacy in subcutaneous tumor models.
- Orthotopic glioblastoma model with convection-enhanced delivery (CED) using an osmotic pump system to mimic clinical intratumoral administration.
Main Results:
- 131I-PARPi, a 1(2H)-phthalazinone, exhibits similar pharmacologic profiles to FDA-approved PARP inhibitor AZD-2281.
- Intratumoral injection of 131I-PARPi delivered significant radiation dose to tumors (134.1 cGy/MBq) with lower doses to off-target organs like the liver and kidney.
- Evidence of radiation damage and cell death via p53 activation was observed in U87-MG cells.
- Treated mice demonstrated significantly longer survival in a subcutaneous model (29 vs. 22 days, P < 0.005).
- CED showed efficient retention of 131I-PARPi in orthotopic brain tumors and rapid clearance from healthy brain tissue.
Conclusions:
- 131I-PARPi demonstrates significant potential as a radiotherapeutic agent for glioblastoma.
- PARP-1 is a relevant and promising target for radionuclide therapy in brain tumors.
- Radiolabeled PARP inhibitors could potentially enhance the standard of care for brain tumor treatment.
Related Concept Videos
02:15SN1 Reaction: Stereochemistry
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
02:05SN1 Reaction: Kinetics
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
02:25SN1 Reaction: Mechanism
Firstly, the haloalkane ionizes to generate a carbocation intermediate and a halide ion. This heterolytic cleavage is highly endothermic with large activation energy. The ionization of the substrate, facilitated by a...
02:42Acidity of 1-Alkynes
The acidic strength of hydrocarbons follows the order: Alkynes > Alkenes > Alkanes. The strength of an acid is commonly expressed in units of pKa — the lower the pKa, the stronger the acid. Among the hydrocarbons, terminal alkynes have lower pKa values and are, therefore, more acidic. For example, the pKa values for ethane, ethene, and acetylene are 51, 44, and 25, respectively, as shown here.
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:27Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...